TF-505
| Code | Size | Price |
|---|
| TAR-T28956-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
TF-505, a steroid 5α-reductase inhibitor, is used potentially for the treatment of benign prostatic hyperplasia.
CAS:
146939-64-2
Formula:
C32H35NO4
Molecular Weight:
497.635
Purity:
0.98
SMILES:
CC[C@H](Oc1ccc(cc1)C(=O)c1cc(CCCC(O)=O)n2ccccc12)c1ccc(CC(C)C)cc1
References
1. Yao Z, Krzyzanski W, Jusko WJ. Assessment of basic indirect pharmacodynamic response models with physiological limits. J Pharmacokinet Pharmacodyn. 2006 Apr;33(2):167-93. PubMed PMID: 16547797.
2. Matsumoto Y, Fujita T, Ishida Y, Shimizu M, Kakuo H, Yamashita K, Majima M, Kumagai Y. Population pharmacokinetic-pharmacodynamic modeling of TF-505 using extension of indirect response model by incorporating a circadian rhythm in healthy volunteers. Biol Pharm Bull. 2005 Aug;28(8):1455-61. PubMed PMID: 16079492.
3. Bay?s M, Rabasseda X, Prous JR. Gateways to clinical trials. March 2003. Methods Find Exp Clin Pharmacol. 2003 Mar;25(2):145-68. PubMed PMID: 12731460.
4. Fujita T, Matsumoto Y, Kimura T, Yokota S, Sawada M, Majima M, Ohtani Y, Kumagai Y. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol. 2002 Sep;54(3):283-94. PubMed PMID: 12236849; PubMed Central PMCID: PMC1874425.